185
Participants
Start Date
April 26, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
September 1, 2027
JNJ-78278343
JNJ-78278343 will be administered.
Cetrelimab
Cetrelimab will be administered by intravenous infusion.
Cabazitaxel
Cabazitaxel will be administered by intravenous infusion.
Docetaxel
Docetaxel will be administered by intravenous infusion.
Apalutamide
Apalutamide will be administered orally.
Enzalutamide
Enzalutamide will be administered orally.
Darolutamide
Darolutamide will be administered orally.
Abiraterone acetate plus prednisone (AAP)
Abiraterone acetate plus prednisone (AAP) will be administered orally.
RECRUITING
Macquarie University, Macquarie University
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
Princess Alexandra Hospital, Woolloongabba
RECRUITING
Icon Cancer Centre Kurralta Park, Kurralta Park
RECRUITING
NYU Langone Health, New York
RECRUITING
Perlmutter Cancer Center at NYU Langone Brooklyn, Brooklyn
RECRUITING
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
RECRUITING
Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
RECRUITING
Hosp Univ Fund Jimenez Diaz, Madrid
RECRUITING
Hosp. Univ. 12 de Octubre, Madrid
RECRUITING
Hosp Univ Hm Sanchinarro, Madrid
RECRUITING
Florida Cancer Specialists, Sarasota
RECRUITING
Start Midwest, Grand Rapids
RECRUITING
Washington University School Of Medicine, St Louis
Janssen Research & Development, LLC
INDUSTRY